

CURRICULUM VITAE



Name: Heng Xie

Email: hengxie@hotmail.com

Phone: 240-671-6156

Fax: 240-671-6156

Position: Chief Medical Officer

Institution: Shenzhen Salubris Pharmaceuticals Co., Ltd.

Location: China & U.S.A.

Education:

- **M.P.H.:** Johns Hopkins University, U.S.A.
- **Ph.D.:** University of Alabama at Birmingham, U.S.A.
- **M.D.:** Zunyi Medical University, P. R. China

Representative Careers:

Heng Xie is the Chief Medical Officer at Shenzhen Salubris Pharmaceuticals Co., Ltd. and a senior adviser to the Mayo Clinic Cancer Center in Rochester, China National Cancer Center, China National Center of Biomedical Analysis, and China Health Promotion Foundation. Before joining Salubris, Dr. Xie was a senior medical officer/program director in the Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI). Dr. Xie oversaw the research bases of two clinical trials – Southwest Oncology Group (SWOG) and ECOG-ACRIN – and directed investigators' initiated/NCI supported phase I-III clinical trials. In addition, he was the Chair of the Cancer Prevention and Control Concept Protocol Review Committee for approving new concepts and protocols for cancer trials and a standing member in the Data Safety Monitoring Committee (DSMC) for both SWOG and ECOG-ACRIN.

Before DCP, Dr. Xie worked as a medical officer for the Cancer Therapy and Evaluation Program (CTEP) at the NCI for 9 years and the Supervisory Medical Officer – Branch Chief for the Division of Clinical Innovation at the National Center for Advancing Translational Sciences (NCATS) for 5 years. He oversaw surgical oncology and clinical oncology programs that support phase I-III cancer treatment trials at the NCI and managed the Clinical Translational Science Awards (CTSA) program at the NCATS. Dr. Xie not only evaluated numerous protocols for clinical trials, but also published 14 funding initiatives and received many NCI/NIH Merit Awards.

Before his 18 years of public service at the NCI/NIH, Dr. Xie was a surgeon in China. Then, he moved to the United States, where he obtained a Ph.D. in molecular and cellular pathology from the

University of Alabama at Birmingham and a M.P.H. from Johns Hopkins University. He also has certification from the Educational Commission for Foreign Medical Graduates. Dr. Xie performed his postdoctoral training at the NCI, focusing on epidemiology, biostatistics and clinical trials. His research and publications specialized in cell signal transduction, EGFR-mediated mechanisms of tumor metastasis, and genetic molecular epidemiology.

Specialty & Present Interest:

Oncological precision medicine and drug development.

Representative papers:

1. **PAR-12-203: A Pre-application for the NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules (X02)**
2. **RFA-TR-12-004: Limited Competition for NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules (UH2/UH3)**
3. **RFA-TR-12-005: Limited Competition for NIH-Industry Pilot Program: Discovering New Therapeutic Uses for Existing Molecules (UH3)**
4. **PA-11-009: Translational Scholar Career Awards in Pharmacogenomics and Personalized Medicine (K23)**
5. **RFA-GM-10-001: Pharmacogenomics Research Network and Knowledge Base (U01/U19)**
6. **RFA-RR-11-004: Limited Competition for Competitive Revision Applications to Accelerating and Enhancing Collaborative Translational Science (UL1)**
7. **RFA-ES-11-006: Deepwater Horizon Disaster Research Consortia: Health Impacts and Community Resiliency (U19)**
8. **PAR-08-025: Quick-Trials for Novel Cancer Therapies and Prevention: Exploratory Grants**
9. **PA-08-133: Correlative Studies with Specimens from Multi-Site Trials (R21).**
10. **PA-08-134: Correlative Studies with Specimens from Multi-Site Trials (R01).**
11. **PA-07-356: Clinical Cancer Therapy and Prevention Research (R01)**
12. **PA-06-295: Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (R21)**
13. **PA-05-165: Exploratory Studies in Cancer Detection, Diagnosis, and Prognosis (R21)**
14. **PA-05-138: Etiology, Prevention, and Treatment of Hepatocellular Carcinoma (P01)**
15. **RFA-GM-04-002: Pharmacogenetics Research Network and Knowledge Base (U01)**